| An immune-based biomarker signature is associated with mortality in COVID-19 patients MS Abers, OM Delmonte, EE Ricotta, J Fintzi, DL Fink, AAA de Jesus, ... JCI insight 6 (1), e144455, 2021 | 382 | 2021 |
| Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates KS Corbett, MC Nason, B Flach, M Gagne, S O’Connell, TS Johnston, ... Science 373 (6561), eabj0299, 2021 | 313 | 2021 |
| Ambient air quality measurements from a continuously moving mobile platform: Estimation of area-wide, fuel-based, mobile source emission factors using absolute principal … T Larson, T Gould, EA Riley, E Austin, J Fintzi, L Sheppard, M Yost, ... Atmospheric Environment 152, 201-211, 2017 | 72 | 2017 |
| Discovering disease-causing pathogens in resource-scarce Southeast Asia using a global metagenomic pathogen monitoring system JA Bohl, S Lay, S Chea, V Ahyong, DM Parker, S Gallagher, J Fintzi, ... Proceedings of the National Academy of Sciences 119 (11), e2115285119, 2022 | 60 | 2022 |
| Multi-pollutant mobile platform measurements of air pollutants adjacent to a major roadway EA Riley, L Banks, J Fintzi, TR Gould, K Hartin, LN Schaal, M Davey, ... Atmospheric Environment 98, 492-499, 2014 | 58 | 2014 |
| Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial I Sagara, SA Healy, MH Assadou, M Kone, BJ Swihart, JL Kwan, J Fintzi, ... The Lancet Infectious Diseases 23 (11), 1266-1279, 2023 | 49 | 2023 |
| Efficient data augmentation for fitting stochastic epidemic models to prevalence data J Fintzi, X Cui, J Wakefield, VN Minin Journal of Computational and Graphical Statistics 26 (4), 918-929, 2017 | 49 | 2017 |
| Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in nonhuman primates KS Corbett, MC Nason, B Flach, M Gagne, S O’Connell, TS Johnston, ... BioRxiv, 2021.04. 20.440647, 2021 | 45 | 2021 |
| Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration D Follmann, MP O’Brien, J Fintzi, MP Fay, D Montefiori, A Mateja, ... Nature Communications 14 (1), 3605, 2023 | 42 | 2023 |
| Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity CM Long, PA Beare, DC Cockrell, J Fintzi, M Tesfamariam, CI Shaia, ... npj Vaccines 6 (1), 38, 2021 | 35 | 2021 |
| A linear noise approximation for stochastic epidemic models fit to partially observed incidence counts J Fintzi, J Wakefield, VN Minin Biometrics 78 (4), 1530-1541, 2022 | 33 | 2022 |
| Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019 JA Rosenthal, SF Awan, J Fintzi, A Keswani, D Ein Annals of Allergy, Asthma & Immunology 126 (1), 93-95, 2021 | 29 | 2021 |
| Comparison of the transmission efficiency and plague progression dynamics associated with two mechanisms by which fleas transmit Yersinia pestis CF Bosio, CO Jarrett, DP Scott, J Fintzi, BJ Hinnebusch PLoS pathogens 16 (12), e1009092, 2020 | 27 | 2020 |
| A deferred-vaccination design to assess durability of COVID-19 vaccine effect after the placebo group is vaccinated D Follmann, J Fintzi, MP Fay, HE Janes, LR Baden, HM El Sahly, ... Annals of internal medicine 174 (8), 1118-1125, 2021 | 26 | 2021 |
| Assessing vaccine durability in randomized trials following placebo crossover J Fintzi, D Follmann Statistics in Medicine 40 (27), 5983-6007, 2021 | 24 | 2021 |
| Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373, eabj0299 KS Corbett, MC Nason, B Flach, M Gagne, S O’Connell, TS Johnston, ... | 22 | 2021 |
| Mycobacterial testing trends, United States, 2009–2015 SG Dean, EE Ricotta, J Fintzi, YL Lai, SS Kadri, KN Olivier, A Zelazny, ... Emerging infectious diseases 26 (9), 2243, 2020 | 20 | 2020 |
| Deconstructing the treatment effect of remdesivir in the adaptive coronavirus disease 2019 (COVID-19) treatment trial-1: implications for critical care resource utilization J Fintzi, T Bonnett, DA Sweeney, NA Huprikar, A Ganesan, MG Frank, ... Clinical Infectious Diseases 74 (12), 2209-2217, 2022 | 16 | 2022 |
| Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial B Zhang, Y Fong, J Fintzi, E Chu, HE Janes, A Kenny, M Carone, ... Nature Communications 15 (1), 7954, 2024 | 13 | 2024 |
| Assessing durability of vaccine effect following blinded crossover in COVID-19 vaccine efficacy trials D Follmann, J Fintzi, MP Fay, HE Janes, L Baden, H El Sahly, TR Fleming, ... medRxiv, 2020 | 12 | 2020 |
